Neuphoria Therapeutics Inc. NEUP

Competitive advantage analysis · healthcare

Corporate Default
Overall moat score
43/100
Developing

Ranked against 712 peers in Biotechnology

About Neuphoria Therapeutics Inc.

Neuphoria Therapeutics Inc., a clinical stage biopharmaceutical company, discovers and develops novel allosteric ion channel modulators for the treatment of central nervous system disorders in Australia. Its lead product candidate includes BNC210, a selective negative allosteric modulator of the a7 for the treatment of social anxiety disorder; and is phase 2b to treat post-traumatic stress disorder. The company also develops … Full NEUP analysis →

Key strengths

  • Revenue Growth Consistent Revenue growth volatility is low (stability score 0.99), suggesting sticky customer base.
  • Operating Leverage in Effect Operating leverage is evident (score 0.93), with margins expanding over time.

Key risks

  • Elevated Debt Risk Debt serviceability is weak (score 0.09), raising refinancing risk.
  • Weak or Negative Cash Flow Cash generation is weak (score 0.39), limiting financial flexibility.

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power

Weak
22
Premium

Signals, strengths and risks for Pricing Power

Premium

Signals, strengths and risks for Cost Advantage

Premium

Signals, strengths and risks for Customer Stickiness

Premium

Signals, strengths and risks for Capital Efficiency

Premium

Signals, strengths and risks for Resilience

Premium

Signals, strengths and risks for Scale & Market Position

Where NEUP ranks in Biotechnology

Neuphoria Therapeutics Inc. ranks #336 of 713 scored companies in Biotechnology by moat score — the top 47%. The widest moat in the group is Royalty Pharma plc (RPRX) at 85/100.

# Company Moat score Rating
332 Annexon, Inc. ANNX 43/100 Developing
333 Palatin Technologies, Inc. PTN 43/100 Developing
334 Savara, Inc. SVRA 43/100 Developing
335 Mersana Therapeutics, Inc. MRSN 43/100 Developing
336 Neuphoria Therapeutics Inc. NEUP 43/100 Developing
337 Rocket Pharmaceuticals, Inc. RCKT 43/100 Developing
338 Vaxcyte, Inc. PCVX 43/100 Developing
339 Chemomab Therapeutics Ltd. CMMB 42/100 Developing
340 Solid Biosciences Inc. SLDB 42/100 Developing

See every Biotech / Pre-Revenue company ranked by moat score →

How NEUP scores on the Corporate Default defenses

Pricing Power

Score 22 · 20% of the moat score

Pricing power is the ability to raise prices without losing volume.

Cost Advantage

Score 34 · 15% of the moat score

A cost advantage means delivering the same product for structurally less — better purchasing, denser distribution, a more automated process.

Customer Stickiness

Score 63 · 15% of the moat score

Stickiness is what makes revenue repeat without being re-won every year.

Capital Efficiency

Score 38 · 18% of the moat score

Capital efficiency asks what the company earns on the money tied up in the business.

Resilience

Score 42 · 17% of the moat score

Resilience is the capacity to get through a bad year on its own terms — enough liquidity, enough interest cover, and enough cash generation to avoid a rescue financing or a forced sale.

Scale & Market Position

Score 65 · 15% of the moat score

Scale matters only when it converts into economics.

How each Corporate Default defense is measured, in full →

Understanding NEUP's moat

What is Neuphoria Therapeutics Inc.'s moat score?

Neuphoria Therapeutics Inc. (NEUP) scores 43 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as developing. It ranks #336 of 713 scored companies in Biotechnology, the top 47%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 712 companies in Biotechnology. Its strongest defense is Scale & Market Position (65/100) and its weakest is Pricing Power (22/100).

How does Neuphoria Therapeutics Inc. compare with other Biotechnology companies?

Neuphoria Therapeutics Inc. ranks #336 of 713 scored companies in Biotechnology by moat score. The widest moat in Biotechnology is Royalty Pharma plc (RPRX) at 85/100. The companies ranked closest are Mersana Therapeutics, Inc. (MRSN) at 43 just above it and Rocket Pharmaceuticals, Inc. (RCKT) at 43 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Corporate Default in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 712 companies in Biotechnology. The defenses are then weighted to produce the overall score out of 100.

Why is Neuphoria Therapeutics Inc. scored with the Corporate Default template?

Most public companies sell a product or a service at a margin, so the moat question is whether that margin survives contact with competitors. The Corporate template scores the six defenses that show up in a general operating company's financial signature: whether it can hold price, produce more cheaply than rivals, keep its customers, earn a return above its cost of capital, withstand a downturn, and turn size into economics.

Which competitive defenses are measured for Neuphoria Therapeutics Inc.?

The Corporate Default template measures 6 defenses, and NEUP scores: Pricing Power (22), Cost Advantage (34), Customer Stickiness (63), Capital Efficiency (38), Resilience (42), Scale & Market Position (65). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000